Evolutionary Genomics, Inc. (FNAM)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2022 | -2.24 Million USD | 31.57% |
| 2021 | -2.7 Million USD | -58.3% |
| 2020 | -1.71 Million USD | -115.84% |
| 2019 | -793.14 Thousand USD | 27.81% |
| 2018 | -1.09 Million USD | -103.59% |
| 2017 | -539.61 Thousand USD | 53.16% |
| 2016 | -1.15 Million USD | -302.81% |
| 2015 | -285.99 Thousand USD | -953.83% |
| 2014 | -27.13 Thousand USD | -40.91% |
| 2013 | -19.26 Thousand USD | -13.08% |
| 2012 | -17.03 Thousand USD | 1.78% |
| 2011 | -17.34 Thousand USD | 26.3% |
| 2010 | -23.52 Thousand USD | -46.86% |
| 2009 | -16.02 Thousand USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 Q3 | - USD | 0.0% |
| 2023 Q1 | - USD | 100.0% |
| 2023 Q2 | - USD | 0.0% |
| 2022 Q2 | -530.35 Thousand USD | -1.08% |
| 2022 Q1 | -524.7 Thousand USD | 21.43% |
| 2022 Q4 | -254.76 Thousand USD | 53.28% |
| 2022 Q3 | -545.27 Thousand USD | -2.81% |
| 2022 FY | -1.85 Million USD | 31.57% |
| 2021 Q2 | -553.7 Thousand USD | -7.78% |
| 2021 FY | -2.7 Million USD | -58.3% |
| 2021 Q4 | -667.84 Thousand USD | 36.92% |
| 2021 Q3 | -1.05 Million USD | -91.2% |
| 2021 Q1 | -513.74 Thousand USD | 69.98% |
| 2020 Q1 | -241.81 Thousand USD | 5.05% |
| 2020 Q2 | -294.79 Thousand USD | -21.91% |
| 2020 Q3 | 535.88 Thousand USD | 281.78% |
| 2020 Q4 | -1.71 Million USD | -419.31% |
| 2020 FY | -1.71 Million USD | -115.84% |
| 2019 Q1 | -200.39 Thousand USD | -8.2% |
| 2019 Q2 | -181.74 Thousand USD | 9.31% |
| 2019 Q3 | -156.32 Thousand USD | 13.99% |
| 2019 Q4 | -254.67 Thousand USD | -62.92% |
| 2019 FY | -793.14 Thousand USD | 27.81% |
| 2018 FY | -1.09 Million USD | -103.59% |
| 2018 Q4 | -185.2 Thousand USD | 30.19% |
| 2018 Q1 | -290.07 Thousand USD | -156.18% |
| 2018 Q2 | -358.04 Thousand USD | -23.43% |
| 2018 Q3 | -265.29 Thousand USD | 25.9% |
| 2017 FY | -539.61 Thousand USD | 53.16% |
| 2017 Q4 | 516.31 Thousand USD | 303.91% |
| 2017 Q3 | -253.2 Thousand USD | 5.35% |
| 2017 Q2 | -267.51 Thousand USD | 49.4% |
| 2017 Q1 | -528.66 Thousand USD | -95.51% |
| 2016 FY | -1.15 Million USD | -302.81% |
| 2016 Q1 | -291.01 Thousand USD | -12.48% |
| 2016 Q2 | -319.54 Thousand USD | -9.8% |
| 2016 Q3 | -271.05 Thousand USD | 15.17% |
| 2016 Q4 | -270.4 Thousand USD | 0.24% |
| 2015 Q1 | -7531.00 USD | -44.24% |
| 2015 Q2 | -7432.00 USD | 1.31% |
| 2015 Q3 | -12.31 Thousand USD | -65.66% |
| 2015 FY | -285.99 Thousand USD | -953.83% |
| 2015 Q4 | -258.72 Thousand USD | -2001.4% |
| 2014 FY | -27.13 Thousand USD | -40.91% |
| 2014 Q2 | -10.32 Thousand USD | -328.46% |
| 2014 Q4 | -5221.00 USD | 43.14% |
| 2014 Q1 | -2410.00 USD | 30.85% |
| 2014 Q3 | -9182.00 USD | 11.08% |
| 2013 Q2 | -8812.00 USD | -155.79% |
| 2013 Q1 | -3445.00 USD | 9.2% |
| 2013 Q3 | -3519.00 USD | 60.07% |
| 2013 Q4 | -3485.00 USD | 0.97% |
| 2013 FY | -19.26 Thousand USD | -13.08% |
| 2012 FY | -17.03 Thousand USD | 1.78% |
| 2012 Q4 | -3794.00 USD | -20.22% |
| 2012 Q3 | -3156.00 USD | -18.42% |
| 2012 Q1 | -7418.00 USD | -260.45% |
| 2012 Q2 | -2665.00 USD | 64.07% |
| 2011 Q1 | -7244.00 USD | 38.32% |
| 2011 Q3 | -6120.00 USD | -218.92% |
| 2011 Q2 | -1919.00 USD | 73.51% |
| 2011 FY | -17.34 Thousand USD | 26.3% |
| 2011 Q4 | -2058.00 USD | 66.37% |
| 2010 FY | -23.52 Thousand USD | -46.86% |
| 2010 Q4 | -11.74 Thousand USD | -37.3% |
| 2010 Q1 | -483.00 USD | -34.54% |
| 2010 Q3 | -8554.00 USD | -211.51% |
| 2010 Q2 | -2746.00 USD | -468.53% |
| 2009 Q4 | -359.00 USD | -14.7% |
| 2009 FY | -16.02 Thousand USD | 0.0% |
| 2009 Q3 | -313.00 USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| America Great Health | -761.42 Thousand USD | -195.272% |
| Ampio Pharmaceuticals, Inc. | -8.63 Million USD | 73.954% |
| Aridis Pharmaceuticals, Inc. | -30.74 Million USD | 92.688% |
| Biora Therapeutics, Inc. | -124.11 Million USD | 98.189% |
| Bio-Path Holdings, Inc. | -16.07 Million USD | 86.017% |
| Better Therapeutics, Inc. | -39.76 Million USD | 94.345% |
| Calithera Biosciences, Inc. | -18.86 Million USD | 88.083% |
| Comera Life Sciences Holdings, Inc. | -18.37 Million USD | 87.767% |
| Gene Biotherapeutics, Inc. | - USD | Infinity% |
| eFFECTOR Therapeutics, Inc. | -35.81 Million USD | 93.722% |
| Eloxx Pharmaceuticals, Inc. | -36.06 Million USD | 93.766% |
| Evelo Biosciences, Inc. | -114.52 Million USD | 98.037% |
| Finch Therapeutics Group, Inc. | -74.75 Million USD | 96.992% |
| Galera Therapeutics, Inc. | -59.08 Million USD | 96.195% |
| Innovation1 Biotech Inc. | -5.98 Million USD | 62.456% |
| Kiromic BioPharma, Inc. | -21.29 Million USD | 89.442% |
| Molecular Templates, Inc. | -8.12 Million USD | 72.326% |
| Navidea Biopharmaceuticals, Inc. | -15.17 Million USD | 85.187% |
| NexImmune, Inc. | -32.34 Million USD | 93.049% |
| Orgenesis Inc. | -55.36 Million USD | 95.939% |
| Panbela Therapeutics, Inc. | -25.26 Million USD | 91.101% |
| Point of Care Nano-Technology, Inc. | -78.01 Thousand USD | -2781.757% |
| PaxMedica, Inc. Common Stock | -18.28 Million USD | 87.708% |
| Scopus BioPharma Inc. | -11.6 Million USD | 80.635% |
| Sorrento Therapeutics, Inc. | -572.84 Million USD | 99.608% |
| Statera Biopharma, Inc. | -174.4 Million USD | 98.711% |
| TRACON Pharmaceuticals, Inc. | -3.58 Million USD | 37.339% |
| Trevena, Inc. | -40.28 Million USD | 94.42% |
| Vaxxinity, Inc. | -56.93 Thousand USD | -3848.888% |
| Vaccinex, Inc. | -20.25 Million USD | 88.898% |
| Vicapsys Life Sciences, Inc. | -1.18 Million USD | -90.19% |
| Viracta Therapeutics, Inc. | -51.05 Million USD | 95.597% |
| ZIVO Bioscience, Inc. | -7.77 Million USD | 71.092% |